Stem Cell-derived Exosome Treatment
Investors 2
| Date | Name | Website |
| - | Korea Inve... | partners.k... |
| - | UTC Invest... | utc.co.kr |
Mentions in press and media 2
| Date | Title | Description |
| 19.02.2025 | Brexogen and BMI Korea Enter Strategic Technology Transfer Agreement for Exosome Therapeutics | Out-licenses BxC-I17e, Exosome-Based Therapeutics for New Indications KRW 3 Billion Non-Refundable Upfront Payment + Milestone Payments + Double-Digit Percentage Royalties SEOUL, South Korea, Feb. 19, 2025 /PRNewswire/ -- Brexogen, a leadin... |
| 07.11.2022 | Brexogen's Exosome Therapy for Atopic Dermatitis, 'BRE-AD01' Accepted for Phase 1 Clinical Trials by US FDA | First entry to clinical trial of exosome for atopic dermatitis The first exosome-based therapeutics in US clinical trial among Korean companies SEOUL, South Korea, Nov. 7, 2022 /PRNewswire/ -- The US FDA granted the initiation of the phase ... |